These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34428831)

  • 21. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
    Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
    Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
    Yoon HY; Lee N; Seong JM; Gwak HS
    Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR;
    J Am Heart Assoc; 2022 Feb; 11(4):e024159. PubMed ID: 35156424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
    JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.
    Coons JC; Stevenson JM; Patel A; Smith AJC; Prebehalla L; Empey PE
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221143246. PubMed ID: 36503270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.
    Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Gong Y; Jiang J; Cui Y
    BMC Cardiovasc Disord; 2022 Mar; 22(1):111. PubMed ID: 35300607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study.
    Meng S; Guo L; Ye Z; Wang J; Ding H; Wu S; Huang R
    Clin Interv Aging; 2022; 17():331-341. PubMed ID: 35400997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Clopidogrel vs Alternative P2Y
    Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Ortega-Paz L; Gong Y; Kerensky RA; Kulick N; McDonough CW; Nguyen AB; Wang Y; Winget M; Yang WE; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Lee CR; Cavallari LH
    J Am Coll Cardiol; 2024 Apr; 83(15):1370-1381. PubMed ID: 38599713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
    Abusnina W; Al-Abdouh A; Bizanti A; Gill G; Houssien A; Alshebani Y; Kanmanthareddy A; Dahal K
    Cardiovasc Revasc Med; 2022 May; 38():54-60. PubMed ID: 34384690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
    Zhang Y; Zhao X; Ye Y; Li Q; Zeng Y
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):183-191. PubMed ID: 34711749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
    Xu S; Liang Y; Chen Y; Gao H; Tan Z; Wang Q; Liu Y; Zhu B; Tao F; Wang Q; Zhao S; Yang L; Zhang Y; Wang Z; Han P; Chen Y; Zhang A; Li C; Lian K
    Drugs Aging; 2022 Sep; 39(9):695-703. PubMed ID: 35995912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
    Povsic TJ; Ohman EM; Roe MT; White J; Rockhold FW; Montalescot G; Cornel JH; Nicolau JC; Steg PG; James S; Bode C; Welsh RC; Plotnikov AN; Mundl H; Gibson CM
    JAMA Cardiol; 2019 Jul; 4(7):680-684. PubMed ID: 31141104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic-Guided Oral P2Y
    Ingraham BS; Farkouh ME; Lennon RJ; So D; Goodman SG; Geller N; Bae JH; Jeong MH; Baudhuin LM; Mathew V; Bell MR; Lerman A; Fu YP; Hasan A; Iturriaga E; Tanguay JF; Welsh RC; Rosenberg Y; Bailey K; Rihal C; Pereira NL
    JACC Cardiovasc Interv; 2023 Apr; 16(7):816-825. PubMed ID: 37045502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.